Ray‐Coquard 2006.

Methods	randomized controlled trial,
Participants	n = 218, breast, sarcoma, lung, ovarian, other solid cancer and hematological malignancies; concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = if body weight < 45 kg 10000 IU sc 2x/week, if body weight 45 kg to < 89 kg 10000 IU sc TIW, if body weight > 89 kg 10000 IU sc 4x/week hb‐target = 12‐14 g/dL planned ESA duration = 12 weeks
Outcomes	Primary: transfusion dependent anemia; secondary: QoL, Hb response predictors, Hb, toxicity, survival, costs
Notes	study number = 37491